Login / Signup

Cyclin-dependent kinase inhibitors enhance programmed cell death protein 1 immune checkpoint blockade efficacy in triple-negative breast cancer by affecting the immune microenvironment.

Jia-Yi WuWei WangLu GaoXiying ShaoXiaojia Wang
Published in: Cancer (2024)
Combination therapy with CDK and PD-L1 immune checkpoint inhibitors affects the immune microenvironment, promotes antitumor immunity, and improves the efficacy of immunotherapy for TNBC.
Keyphrases
  • combination therapy
  • cell cycle
  • stem cells